Phase 3 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple sclerosis (MS) based on a specific set of recognised diagnostic standards called the revised McDonald criteria.
- People who have shown signs of recent MS activity, as defined by the trial's guidelines.
- People whose neurological condition has been stable for at least 30 days before joining.
- People who score between 0 and 6.0 (inclusive) on a standard MS disability scale called the EDSS, which measures how much MS affects daily functioning.
Who may not be able to join:
- People who have been diagnosed with primary progressive or secondary progressive MS.
- People who have had MS for more than 15 years and score 2.0 or below on the EDSS scale at the screening stage.
- People who are unable to have an MRI scan, or for whom an MRI scan would be medically unsuitable.
- People who have known serious allergic reactions or medical reasons preventing them from taking corticosteroids (a type of medication), including a drug called methylprednisolone, or any ingredients in the trial medication (confirm with trial site for full details).
- People who have, or have had in the past, certain medical conditions listed in the trial protocol (confirm with trial site for the full list).
- People who have recently received, are currently receiving, or are planning to receive certain medications or treatments that are not permitted under the trial protocol (confirm with trial site for the full list).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Minji Ma, Celltrion, Inc.
Phone: +82 32 850 5791
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Area under the concentration-time curve in PK group; Total number of new GdE lesions on T1-weighted brain MRI in Main study group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.